Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

Potential use of biomarkers for the clinical evaluation of sarcoidosis

Amir Mousapasandi, Cristan Herbert, Paul Thomas
DOI: 10.1136/jim-2020-001659 Published 1 April 2021
Amir Mousapasandi
1 School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amir Mousapasandi
Cristan Herbert
1 School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Thomas
1 School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
2 Department of Respiratory Medicine, Prince of Wales' Hospital and Prince of Wales' Clinical School, University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Sarcoidosis is a systemic granulomatous disease of unknown etiology and pathogenesis with a heterogeneous clinical presentation. In the appropriate clinical and radiological context and with the exclusion of other diagnoses, the disease is characterized by the pathological presence of non-caseating epithelioid cell granulomas. Sarcoidosis is postulated to be a multifactorial disease caused by chronic antigenic stimulation. The immunopathogenesis of sarcoidosis encompasses a complex interaction between the host, genetic factors and postulated environmental and infectious triggers, which result in granuloma development.

The exact pathogenesis of the disease has yet to be elucidated, but some of the inflammatory pathways that play a key role in disease progression and outcomes are becoming apparent, and these may form the logical basis for selecting potential biomarkers.

Biomarkers are biological molecules that are altered pathologically. To date, there exists no single reliable biomarker for the evaluation of sarcoidosis, either diagnostically or prognostically but new candidates are emerging. A diagnosis of sarcoidosis ideally requires a biopsy confirming non-caseating granulomas, but the likelihood of progression that requires intervention remains unpredictable. These challenging aspects could be potentially resolved by incorporating biomarkers into clinical practice for both diagnosis and monitoring disease activity.

This review outlines the current knowledge on sarcoidosis with an emphasis on pulmonary sarcoidosis, and delineates the understanding surrounding the implication of biomarkers for the clinical evaluation of sarcoidosis.

Background

Epidemiology of sarcoidosis

The incidence and prevalence of sarcoidosis is reported to be highest in Nordic countries (an incidence of 5–40 per 100 000 per year and a prevalence of 0.16%) and in African-Americans (incidence of 17.8–46 per 100 000 and a prevalence of 0.14%).1–3 The incidence is reported to be significantly lower in East Asia countries with Japan having an overall incidence of 1.01 per 100 000 and Korea having an incidence rate of 0.85 per 100 000.4 5

The peak age for sarcoidosis onset ranges from 30 to 55 years. Gender plays a role in manifestation of sarcoidosis, as males with sarcoidosis are diagnosed 3–10 years earlier than females who also have a higher prevalence.6 Mortality rates in sarcoidosis ranges from 1% to 8% depending on the type and location of the disease and other health factors.7

Etiology of sarcoidosis

The exact etiology of sarcoidosis remains unknown with no single genetic, infectious or environmental factor being identified to have a causal link to sarcoidosis.8

The current pathophysiological concept suggests a model in which sarcoidosis is caused by the combination of genetic polymorphisms creating a tendency to a specific immune response, associated with exposure to environmental or infectious agents.9 The sequence of events for the progression of sarcoidosis is depicted in figure 1.10 11

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The sequence of events with the influence of different etiologies leading to granuloma formation.

Genetics

A genetic tendency in the development of sarcoidosis is demonstrated by familial clustering of sarcoidosis, the varying prevalence and subtype of presentation among different ethnicities and a higher occurrence in twin studies. African-Americans have a higher prevalence of sarcoidosis (3.8-fold to 4.0-fold greater risk than European Americans), a higher rate of extrathoracic involvement and more chronic and severe disease with a lower rate of remission. Twins studies indicate an 80-fold increased risk among monozygotic twins, and a 7-fold increase among dizygotic twins.12–14

Case-control studies have identified that HLA alleles, responsible for the CD4+ T lymphocyte polypeptides in the HLA class I and II antigens, as being associated with specific disease subtypes and tendencies to sarcoidosis, for example, Lofgren’s syndrome, a type of sarcoidosis with a good prognosis, being linked to the HLA-DR3 allele, in contrast to the HLA-DR15 allele which carries a worse prognosis.15 16 These discoveries were further expanded by Genome Wide Association Studies and Case-Control Etiologic Study of Sarcoidosis (ACCESS) that also show the importance of genetic components in sarcoidosis.11 17

Infectious agents

The radiological, clinical and immunological similarities between tuberculosis (TB) and sarcoidosis suggest the possible role of mycobacteria as an etiological agent.18 The OR for the presence of mycobacterial DNA in tissue samples of patients with sarcoidosis compared with those from healthy subjects was found to be 9-fold to 19-fold and mycobacterial DNA was present in almost 30% of sarcoidosis biopsy specimens from sites such lymph nodes, lung, skin and others,19–21 but to date, the culture of live organisms has been rare. Propionibacterium acnes has been isolated from culture in 78% of sarcoid lesions, which suggest a role for this organism in sarcoidosis; however, P. acnes was also found in 20% of non-sarcoid lymph nodes.22 Animal models have also indicated that P. acnes can induce antigen-driven granulomatous inflammation.23 Diseases with similar pathological and immunological features that resemble sarcoidosis, such as hypersensitivity pneumonitis and chronic beryllium disease, indicate that it is unclear whether sarcoidosis has an infectious etiology or not and more studies on the subject are required to investigate the exact role of these putative infectious agents.24–26

Environmental agents

Exposure to metals and minerals such as beryllium, chromium, aluminum, titanium, zirconium, talc and nickel has been shown to induce sarcoid-like granulomas.27 Epidemiological studies have identified positive associations between occupations such as metal-working, fire-fighting and the handling of building supplies and sarcoidosis.11 28 29

Tobacco smoking decreases the risk of sarcoidosis, possibly because smoking deactivates M2 alveolar macrophages and the macrophage is thought to be pivotal in the pathogenesis of the disease.30 The ACCESS studies have identified several environmental exposures associated with an increased risk of sarcoidosis including agricultural materials, pesticides, insecticides and microbial aerosols (mouldy and musty odours).11 Although there are many findings implicating environmental agents as risk factors, the current evidence does not strongly favor a single environmental or occupational exposure, and may implicate a range of precipitants.31

Pathogenesis of sarcoidosis

The histopathological appearance of sarcoidosis is that of non-caseating granulomas formed as the result of aberrant cell-mediated immune responses to unknown antigens. Sarcoid granulomas are characterized by a central core of giant cells, epithelioid cells and helper T cells (Th).16 32 This central area is surrounded by monocytes, mast cells, CD8+ and CD4+ T lymphocytes, B lymphocytes and fibroblasts, which in turn are surrounded by lamellar rings of hyaline collagen (figure 1). The proportions of lymphocytic infiltrate and fibrosis surrounding the central core vary depending on the patient and disease duration. Additional histopathological elements of sarcoid granulomas that may be present include Schaumann bodies, birefringent crystalline particles and asteroid bodies, which are biomolecules and mineral components incorporated into the granulomas.33

As a result of antigen-presentation by dendritic cells and subsequent T cell activation, monocytes are recruited to the site of inflammation. In the case of incomplete antigenic clearance, the monocytes build up and eventually mature into epithelioid cells. Following the cell-mediated immune responses, T lymphocytes are also recruited and infiltrate the tissue, and a granuloma develops (figure 2). A sarcoid granuloma is thought to be a dynamic structure recruiting newly formed monocytes, which gradually penetrate the core where they mature into epithelioid cells.34 35

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Overview of the postulated immunopathogenesis of sarcoidosis. The immunopathogenesis of sarcoidosis showing three different outcomes of the disease and the dominant immunological markers involved in each. GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; IFN-γ, interferon gamma; NKT, natural killer cells; TCR, T-cell receptors; TNF-α, tumor necrosis factor alpha.

Th1 cells

Interleukin-12 and interleukin-18 (IL-12 and IL-18 as cytokines) are activated and released by dendritic cells to promote Th1 proliferation and interferon gamma (IFN-γ) production.36 Subsequently, IL-18 amplifies the expression of tumour necrosis factor alpha (TNF-α), IL-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) that are produced from activated dendritic cells which in turn enhance the CD4+T cells and formation of granulomatous inflammation in a synergistic manner.37 38

IFN-γ promotes the production of T-bet and the chemokine receptor CXCR3 that result in a positive feedback-loop which further increases IFN-γ through Th1 mechanisms. Increased levels of IFN-γ from the feedback-loop decreases the expression of Th2 cytokine transcription and the production of Th2 cytokines such as IL-4 and IL-13.39 40

Despite the dominant role of Th1 cells in sarcoidosis, recent studies show that Th17 cells also play a role. Th17 cells produce IL-17A which is vital for formation of mature granulomas. Additionally, Th17 cells appear to be an important Th cell subtype in bronchoalveolar lavage fluid (BALF) of patients with sarcoidosis and have elevated levels of IFN-γ.41–44

Th2 cells

Fibrosis in sarcoidosis is thought to be caused by the shift in the immune response from Th1 to Th2 dominance.45 IL-13, a Th2 cytokine, stimulates transforming growth factor beta (TGF-β) activity which induce the transformation of fibroblasts into myofibroblasts. Fibrosis in sarcoidosis may also be related to the role of elevated chemokine ligand 2 (CCL2, a Th2 chemokine) as it prevents fibroblast cell death through IL-6/STAT3 signaling.46 47 A summary of the contribution of Th1, Th17 and Th2 cells to the pathogenesis of sarcoidosis is depicted in figure 2.

Clinical diagnosis

Currently, most of the diagnostic and monitoring tests available require an invasive biopsy. Hence, development of a less invasive test for sarcoidosis is a goal of ongoing research. To date, there exist no ‘gold standard’ diagnostic criteria. However, a presumptive diagnosis of sarcoidosis can be made following radiological evidence of sarcoidosis such as bilateral symmetrical hilar lymphadenopathy, clinical evidence of sarcoidosis such as erythema nodosum and pulmonary involvement or histological finding of non-caseating granuloma.48 The latest American Thoracic Society clinical practice guidelines do not make a definitive statement in relation to biopsy. Endobronchial ultrasound and biopsy has a high yield, but depends on the presence of proximal mediastinal or hilar lymphadenopathy.49

The presentation of sarcoidosis may be an incidental asymptomatic finding on imaging, such as intrathoracic lymphadenopathy on chest radiograph in 87% of cases or by clinical presentation with cough or breathlessness in symptomatic individuals. Pulmonary disease is present in up to 97% of cases, together with cutaneous, hepatosplenomegaly, central nervous system (CNS), ocular and cardiac sarcoidosis.3 50

Spontaneous remission occurs in most cases of sarcoidosis, but 25%–40% of patients will have a chronic and protracted course and it can be the cause of death in approximately 5% of cases.51

Biomarkers for clinical evaluation

Biomarkers can be considered as indicators of normal or pathological processes, and the use of potential biomarkers to provide a diagnosis and to monitor disease activity remain the focus of ongoing research. Several approaches have been adopted to detect novel biomarkers in BALF, exhaled breath condensate (EBC) and serum using proteomic analysis, ELISA of specific candidate meditators and genome-based approaches.52–54 Many of these reports require to be conducted in large-scale studies for better external validity and to be able to distinguish the different phases of the disease such as radiological staging, lung function and extrathoracic involvement.52 55

Furthermore, studies identifying novel biomarkers may guide approaches to expand our understanding of this puzzling disease. Despite many potential biomarkers being recognized, a lack of sensitivity and specificity have hampered clinical usage, therefore necessitating further research in this area.56

Serum

The traditional approach to investigate the pathogenesis of a disease is by examining the serum biomarkers. Initially, it was believed that analyzing serological biomarkers would be beneficial in sarcoidosis as sarcoidosis is a multiorgan disease and these might better represent the underlying systemic inflammation, but local inflammation can be assessed, for example, in the breath.57 58 However, despite many such biomarkers being discovered to be associated with sarcoidosis, none has been shown to have the adequate accuracy to be used for routine diagnosis, with the possible exception of ACE. Some serum biomarker levels may be altered in single organ disease, but not in others, for example, in pulmonary sarcoidosis the systemic depletion of peripheral lymphocytes (peripheral anergy) may lead to serum biomarkers not being representative of the disease state in pulmonary sarcoidosis, whereas in, for example, solitary sarcoid uveitis, systemic markers may not be altered at all.59

Potential serum biomarkers in patients with sarcoidosis have included angiotensin converting enzyme (ACE), serum amyloid A, cytokines, chemokines, microRNAs (miRNAs), chitotriosidase and lysosomes as summarized in table 1.60–77 Serum chitotriosidase was shown to have relatively accurate diagnostic ability with very high sensitivity and specificity, however, another study with different cut-off values indicated substantially lower diagnostic values (sensitivity and specificity of 88.6% and 92.8% for cut-off of 48.8 nmol/hour/mL and 82.5% and 70% for cut-off of 100 nmol/hour/mL, respectively).62 78 Further research should be conducted to correctly delineate the cut-off value that provides optimal diagnostic accuracy, and with more sample size and clinical context, however, it is possible to have different cut-offs for various types of patients or clinical backgrounds.

View this table:
  • View inline
  • View popup
Table 1

Serum biomarkers in patients with sarcoidosis

To date, only ACE been adopted for clinical usage due to the low sensitivity/specificity and lack of reproducibility of other potential novel biomarkers, although chitotriosidase may be useful for disease monitoring, progression and response to treatment. A study assessing the ACE levels of 3277 patients with sarcoidosis concluded that despite the common practice, ACE should not be used in clinical practice for the diagnosis of sarcoidosis.79

Serum biomarkers could be valuable in distinguishing between granulomatous diseases such as TB and sarcoidosis. Serum leptin and intercellular adhesion molecule 1 levels were shown to be significantly elevated in patients with sarcoidosis rather than in TB.80 Another serum biomarker, adiponectin, which is an anti-inflammatory protein was differentially expressed in patients with sarcoidosis compared with healthy individuals.81 Soluble CD163 was also significantly elevated in patients with sarcoidosis and its level associated with serum ACE and soluble IL-2 receptor levels, an important marker of macrophage activity involved in sarcoidosis, hence CD163 could provide insight on important aspects of disease activity.82 Biomarkers could be used to identify the organ involved in sarcoidosis. Serum ACE and soluble IL-2R levels were significantly lower in isolated cardiac sarcoidosis than systemic sarcoidosis, whereas B-type natriuretic peptide (BNP) was elevated in cardiac sarcoidosis, thus BNP might be a useful marker for detecting cardiac involvement in conjunction with other clinical tests.83 Advanced imaging for cardiac sarcoidosis such as cardiac magnetic resonance and 18FFDG PET have proven valuable in establishing clinical assessment of the disease, and these techniques coupled with specific organ biomarkers could provide a possible diagnostic approach when biopsy is difficult to perform in extrathoracic organ involvement.84 Similarly, attempts have been made to identify serum neurosarcoidosis biomarkers, and serum S100B which is a calcium-binding protein was found to be elevated and correlated with CNS injury in neurosarcoidosis.85

Neurosarcoidosis and cardiac sarcoidosis remain difficult to diagnose and remain based on a combined clinical picture with MRI/PET and other features such as CSF ACE and oligoclonal bands, or the presence of more accessible disease to biopsy.

Bronchoalveolar lavage fluid

Since pulmonary disease is common, sampling the lung could provide valuable insight about sarcoidosis activity and clinical evaluation. Changes in the inflammatory profile in BALF or breath could reflect the activity of components of sarcoidosis-related inflammation, that is, macrophages and lymphocytes.86 Sarcoidosis is characterized by an increase in BALF lymphocytes and the CD4/CD8 ratio (1.7±1 in healthy individuals vs 9.3±5.0 in symptomatic individuals).86 A meta-analysis demonstrated that the BALF CD4/CD8 ratio provides a sensitivity of 70% and specificity of 83% for sarcoidosis, a better accuracy than ACE, a marker commonly used in clinical practice. No clear cut-off value was found as the values ranged from 2 to 4 between studies, therefore it is crucial to find a value to provide optimal diagnostic accuracy. The value, CD4/CD8 ratio ≥3.5, was useful for patients who presented with typical clinical and radiological manifestation of the disease, but, the ratio is not selective enough to be employed on its own and must be integrated with other established diagnostic methods.87

Furthermore, matrix metalloproteinase 12 (MMP12), an elastase enzyme produced by macrophages is known to have elevated gene and protein expression in BALF of patients with sarcoidosis and the levels were correlated with disease severity.88 The altered MMP12 expression in BALF resulted in animal studies being conducted, which demonstrated that MMP12 knockout mice had a significant reduction in granuloma formation and reduced expression of IFN-γ, an important mediator in sarcoidosis pathogenicity. These findings suggest a critical role for MMP12 in the chronicity of granulomatous inflammation.89 Another BALF biomarker is the T-cell subset CD4+ Vα2.3+, which is associated with a better prognosis and potentially may be used as a surrogate prognostic marker.90

As in serum, a range of chemokines, cytokines, ILs and lymphocytes are altered in the BALF of patients with sarcoidosis, as summarized in table 2. For instance, patients with Löfgren’s syndrome, who have a better prognosis, were established to have lower IFN-γ and TNF-α messenger RNA (mRNA) levels in their BALF, pro-inflammatory mediators involved in sarcoidosis pathology, than HLA subtypes with worse prognosis.91

View this table:
  • View inline
  • View popup
Table 2

BALF biomarkers in patients with sarcoidosis

Exhaled breath condensate

An alternative method to assess the BALF is by collecting EBC which is a non-invasive method of collecting exhaled breath containing the airway lining fluid (ALF) and soluble exhaled gases. The ALF can be analyzed by collecting BALF, however collection requires bronchoscopy and therefore is not a feasible approach for routine monitoring.92 Moreover, bronchoscopy is an invasive technique that has complications such as pneumothorax (0%–4%), desaturation (0.7%–76.3%), bleeding (2.5%–89.9%), arrhythmia (8%–25.7%) and patient discomfort (55.4%–96.3%), making it impractical as a repeated routine test and would likely have low acceptance as a frequent test.93

EBC samples the ALF, and therefore can assess airway inflammation and disease activity94 95 with potential EBC biomarkers linked to the underlying pathophysiology of respiratory conditions, including asthma, cystic fibrosis, chronic obstructive pulmonary disease and sarcoidosis.72 96–99

The concentration of total protein and some inflammatory modulators are significantly elevated in EBC from sarcoidosis compared with healthy subjects and this elevation is in agreement with studies of BALF. A subanalysis of these proteins and inflammatory markers is required to specifically identify the important cytokines and signaling proteins involved in sarcoidosis and are differentially expressed.100–103 Original work from our laboratory has demonstrated that EBC TGF-β1, an inflammatory mediator involved in sarcoidosis, and neopterin are elevated in patients with sarcoidosis compared with healthy individuals.102

Another advantage of evaluating EBC biomarkers is that the technique is totally non-invasive. Such a measurement has potential application in serial monitoring of disease activity which lends itself to being able to indicate regression or relapse. Potential biomarkers in BALF and EBC such as TNF-α, miRNAs, cytokines, IFN-γ and extracellular vesicles (EV) (exosomes) have been found to differ between patients with sarcoidosis and healthy controls and hence identified as possible diagnostic and prognostic tools which need to be tested in prospective studies.60 100 104–107 In order to further develop the EBC technique in clinical care, much work has been focused on standardisation of EBC collection for use in clinical practice.100

A summary of key studies which demonstrate the BALF biomarkers that are differentially expressed in patients with sarcoidosis compared with healthy controls is demonstrated in table 2 but more work is required to better characterize EBC findings in sarcoidosis and establish those that are most reliable.

Limitation of biomarkers

The use of biomarkers for sarcoidosis may be challenging for several reasons. First, the criteria for the diagnosis for the diagnosis of sarcoidosis rely on the clinical presentation, biopsy result with non-caseating granulomata and the exclusion of other diagnoses, which can affect the certainty of a diagnosis when assessing the accuracy of a newly developed diagnostic biomarker.108 Furthermore, sarcoidosis is a systemic disease in which multiple organs may be affected to a varying extent. Therefore, unidimensional biomarkers are unlikely to encapsulate the whole spectrum of the disease. Techniques to overcome this problem are to use a combination of several biomarkers or to study those related to specific organ involvement.109 In addition, it is likely that some biomarkers will reflect active macrophage and lymphocytic inflammation, while other may reflect the healing process, and yet others represent a pathway to ongoing fibrosis.43

Despite some research, no novel biomarkers have been adopted into clinical practice due to their relatively low accuracy, sensitivity and specificity.60 Therefore, biomarkers remain an area that requires more study.

Discovery and validation of novel biomarkers

While many advances have been made in understanding the pathogenesis and the identification of biomarkers that are plausible indicators of sarcoidosis, novel aspects of the basic mechanisms are becoming apparent as being involved in disease progression and resolution and may offer opportunities for novel biomarkers. Some of these novel biomarkers that have shown initial success and require more research include miRNAs and exosomes.

MicroRNAs

miRNAs are a class of regulatory molecules suggested to be as prospective biomarkers with the possible involvement in sarcoidosis pathophysiology.104 110 miRNAs are non-coding, single-stranded RNAs composed of 18–25 nucleotides, and the importance of miRNA altered regulation in lung disease is becoming increasingly evident.111 miRNAs likely play a role in both inflammation and granuloma formation, hence a significant component of sarcoidosis pathophysiology.112 miRNAs are able to change the function of various inflammatory and apoptosis signaling pathways by inhibiting the post-transcriptional gene expression via mRNA or altering protein translation.111 113 The inflammatory regulation related to sarcoidosis includes modulation of T-cell differentiation, IFN-γ expression, Th1 cells and IL-2R.114

Multiple studies demonstrate the relationship between dysregulation of several miRNAs and sarcoidosis.115 116 As highlighted in BALF and serum, many miRNAs have altered expression in sarcoidosis, and some are associated with disease severity. It is unclear whether these miRNAs would be elevated in sarcoidosis EBC samples, complicated by the fact that extracellular miRNAs are mostly encapsulated inside EV.117

Exosomes

Exosomes are small, 30–120 nm in diameter, cell-derived EV and are secreted from most cell types.117 Exosomes mainly serve as a means of protection to transfer cell surface molecules, proteins, miRNAs and DNAs to specific location for intercellular communication and to protect them from enzymatic breakdown.118

Exosomes are biologically active EV that are tightly regulated thorough various mediators and pathways. miRNAs are mostly encapsulated within exosomes and therefore exosome isolation improves the sensitivity of miRNA expression and identification,119 although not all studies have confirmed this view with miRNAs being also present outside exosomes and bound to proteins such as Argonaute 2.120 121

The number and the contents of exosomes in body fluids increase in cancer and sarcoidosis, however exosomal function in sarcoidosis pathophysiology remains poorly understood.107 122 Sarcoidosis BALF exosomal miRNA and cytokines were elevated, for example, miRNA-146a.107 123 BALF exosomes from patients with sarcoidosis induced higher levels of IFN-γ and IL-13 production by epithelial cells therefore illustrating an association with the underlying immunopathogenesis of sarcoidosis.107 We have shown that EBC exosomes are able to be isolated and exosome-induced production of TNF-α was greater in monocytes from patients than from controls and miRNAs and mRNA involved in sarcoidosis pathology was expressed higher in serum exosomes of patients.124 A number of studies have investigated miRNA expression in pulmonary sarcoidosis.114 Several investigated miRNA expression in peripheral blood, blood cells bronchoalveolar cells, exosomal/EV miRNA in BALF but none studied exosomal miRNA expression in EBC.61 115 125–131 Thus, there is a need for more studies to be conducted with larger numbers of subjects, different sample sources such as EBC and to target known mediators of sarcoidosis.

Moreover, the exosomal miRNAs changes were not limited to pulmonary sarcoidosis as a study indicated several exososomal miRNAs levels were higher in patients with cardiac sarcoidosis, hence further illustrating the potential of miRNAs as biomarkers and the possibility of using specific biomarkers for detecting vital organ involvement.132

Conclusion and future research

Evaluating exosomal and non-exosomal miRNAs and cytokine expression in EBC samples has remained an unexplored area in the literature and thus requires further investigation. Furthermore, our preliminary data indicate that exosomes and miRNAs regulating key sarcoidosis cytokines that are differentially expressed in EBC, hence more research is required to identify and validate sarcoidosis biomarkers that have the advantage of being non-invasive, sensitive and amenable to repeated sampling.124 Many recent studies have demonstrated a variety of mediators involved in the immunopathogenesis of sarcoidosis and the levels were shown to be differentially expressed in sarcoidosis, indicating that they may be potential biomarkers. However, uncertainty remains as to which aspect of clinical assessment, diagnosis, prognosis or disease activity, these biomarkers could be applied. The pattern in which biomarkers were expressed in organ-specific sarcoidosis is not always consistent with other forms of the diseases, hence more focused studies are mandated to better characterize the nature of biomarkers in different disease forms. Likewise, long-term studies with a baseline profile of the potential markers would be helpful in indicating prognosis, but the analysis will be complex with many variables including gender, ethnicity, MHC/genomic and other variables requiring assessment, and the results will need to be validated carefully.

Acknowledgments

The original figure (figure 2) was created using Servier Medical Art Templates, which are licensed under a Creative Common Attribution 3.0 Unported License: https://smart.servier.com.

Footnotes

  • Twitter @AmirMP_

  • Contributors AM planned and wrote the initial draft of the manuscript; CH and PT edited the manuscript for submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

References

  1. ↵
    1. Arkema EV ,
    2. Grunewald J ,
    3. Kullberg S , et al
    . Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016;48:1690–9.doi:10.1183/13993003.00477-2016 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27471207
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Baughman RP ,
    2. Field S ,
    3. Costabel U , et al
    . Sarcoidosis in America. analysis based on health care use. Ann Am Thorac Soc 2016;13:1244–52.doi:10.1513/AnnalsATS.201511-760OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/27509154
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ungprasert P ,
    2. Carmona EM ,
    3. Utz JP , et al
    . Epidemiology of sarcoidosis 1946-2013: a population-based study. Mayo Clin Proc 2016;91:183–8.doi:10.1016/j.mayocp.2015.10.024 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26727158
    OpenUrlCrossRefPubMed
  4. ↵
    1. Yoon H-Y ,
    2. Kim HM ,
    3. Kim Y-J , et al
    . Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res 2018;19:158. doi:10.1186/s12931-018-0871-3 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30153830
    OpenUrlPubMed
  5. ↵
    1. Morimoto T ,
    2. Azuma A ,
    3. Abe S , et al
    . Epidemiology of sarcoidosis in Japan. Eur Respir J 2008;31:372–9.doi:10.1183/09031936.00075307 pmid:http://www.ncbi.nlm.nih.gov/pubmed/17959635
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Arkema EV ,
    2. Cozier YC
    . Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis 2018;9:227–40.doi:10.1177/2040622318790197 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30364496
    OpenUrlPubMed
  7. ↵
    1. Gerke AK
    . Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med 2014;20:472–8.doi:10.1097/MCP.0000000000000080 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25029298
    OpenUrlPubMed
  8. ↵
    1. Ramachandraiah V ,
    2. Aronow W ,
    3. Chandy D
    . Pulmonary sarcoidosis: an update. Postgrad Med 2017;129:149–58.doi:10.1080/00325481.2017.1251818 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27766929
    OpenUrlCrossRefPubMed
  9. ↵
    1. Dubrey S ,
    2. Shah S ,
    3. Hardman T , et al
    . Sarcoidosis: the links between epidemiology and aetiology. Postgrad Med J 2014;90:582–9.doi:10.1136/postgradmedj-2014-132584 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25230946
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Semenzato G
    . Access: a case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:83–6.pmid:http://www.ncbi.nlm.nih.gov/pubmed/16053022
    OpenUrlPubMedWeb of Science
  11. ↵
    1. Barnard J ,
    2. Rose C ,
    3. Newman L , et al
    . Job and industry classifications associated with sarcoidosis in a case-control etiologic study of sarcoidosis (access). J Occup Environ Med 2005;47:226–34.doi:10.1097/01.jom.0000155711.88781.91 pmid:http://www.ncbi.nlm.nih.gov/pubmed/15761318
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Saidha S ,
    2. Sotirchos ES ,
    3. Eckstein C
    . Etiology of sarcoidosis: does infection play a role? Yale J Biol Med 2012;85:133–41.pmid:http://www.ncbi.nlm.nih.gov/pubmed/22461752
    OpenUrlPubMed
  13. ↵
    1. Nessrine A ,
    2. Zahra AF ,
    3. Taoufik H
    . Musculoskeletal involvement in sarcoidosis. J Bras Pneumol 2014;40:175–82.doi:10.1590/s1806-37132014000200012 pmid:http://www.ncbi.nlm.nih.gov/pubmed/24831403
    OpenUrlPubMed
  14. ↵
    1. Sverrild A ,
    2. Backer V ,
    3. Kyvik KO , et al
    . Heredity in sarcoidosis: a registry-based twin study. Thorax 2008;63:894–6.doi:10.1136/thx.2007.094060 pmid:http://www.ncbi.nlm.nih.gov/pubmed/18535119
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Grunewald J ,
    2. Grutters JC ,
    3. Arkema EV , et al
    . Sarcoidosis. Nat Rev Dis Primers 2019;5:45.doi:10.1038/s41572-019-0096-x pmid:http://www.ncbi.nlm.nih.gov/pubmed/31273209
    OpenUrlPubMed
  16. ↵
    1. Valeyre D ,
    2. Prasse A ,
    3. Nunes H , et al
    . Sarcoidosis. The Lancet 2014;383:1155–67.
    OpenUrlPubMed
  17. ↵
    1. Adrianto I ,
    2. Lin CP ,
    3. Hale JJ , et al
    . Genome-Wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS One 2012;7:e43907. doi:10.1371/journal.pone.0043907 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22952805
    OpenUrlCrossRefPubMed
  18. ↵
    1. Drake WP ,
    2. Pei Z ,
    3. Pride DT , et al
    . Molecular analysis of sarcoidosis tissues for Mycobacterium species DNA. Emerg Infect Dis 2002;8:1334–41.doi:10.3201/eid0811.020318 pmid:http://www.ncbi.nlm.nih.gov/pubmed/12453366
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Dubaniewicz A ,
    2. Trzonkowski P ,
    3. Dubaniewicz-Wybieralska M , et al
    . Mycobacterial heat shock protein-induced blood T lymphocytes subsets and cytokine pattern: comparison of sarcoidosis with tuberculosis and healthy controls. Respirology 2007;12:346–54.doi:10.1111/j.1440-1843.2007.01076.x pmid:http://www.ncbi.nlm.nih.gov/pubmed/17539837
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gupta D ,
    2. Agarwal R ,
    3. Aggarwal AN , et al
    . Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J 2007;30:508–16.doi:10.1183/09031936.00002607 pmid:http://www.ncbi.nlm.nih.gov/pubmed/17537780
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Svendsen CB ,
    2. Milman N ,
    3. Rasmussen EM , et al
    . The continuing search for Mycobacterium tuberculosis involvement in sarcoidosis: a study on archival biopsy specimens. Clin Respir J 2011;5:99–104.doi:10.1111/j.1752-699X.2010.00205.x pmid:http://www.ncbi.nlm.nih.gov/pubmed/21410902
    OpenUrlPubMed
  22. ↵
    1. Asakawa N ,
    2. Uchida K ,
    3. Sakakibara M , et al
    . Immunohistochemical identification of Propionibacterium acnes in granuloma and inflammatory cells of myocardial tissues obtained from cardiac sarcoidosis patients. PLoS One 2017;12:e0179980. doi:10.1371/journal.pone.0179980 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28686683
    OpenUrlPubMed
  23. ↵
    1. Mukherjee S
    . Is Propionibacterium acnes the cause of sarcoidosis? Thorax 2004;59:942.
  24. ↵
    1. Celada LJ ,
    2. Hawkins C ,
    3. Drake WP
    . The etiologic role of infectious antigens in sarcoidosis pathogenesis. Clin Chest Med 2015;36:561–8.doi:10.1016/j.ccm.2015.08.001 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26593133
    OpenUrlPubMed
  25. ↵
    1. DiGiulio DB ,
    2. Romero R ,
    3. Amogan HP , et al
    . Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One 2008;3:e3056. doi:10.1371/journal.pone.0003056 pmid:http://www.ncbi.nlm.nih.gov/pubmed/18725970
    OpenUrlCrossRefPubMed
  26. ↵
    1. Hanak V ,
    2. Kalra S ,
    3. Aksamit TR , et al
    . Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006;100:610–5.doi:10.1016/j.rmed.2005.08.005 pmid:http://www.ncbi.nlm.nih.gov/pubmed/16194601
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Newman KL ,
    2. Newman LS
    . Occupational causes of sarcoidosis. Curr Opin Allergy Clin Immunol 2012;12:145–50.doi:10.1097/ACI.0b013e3283515173 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22314258
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kucera GP ,
    2. Rybicki BA ,
    3. Kirkey KL , et al
    . Occupational risk factors for sarcoidosis in African-American siblings. Chest 2003;123:1527–35.doi:10.1378/chest.123.5.1527 pmid:http://www.ncbi.nlm.nih.gov/pubmed/12740270
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Prezant DJ ,
    2. Dhala A ,
    3. Goldstein A , et al
    . The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest 1999;116:1183–93.doi:10.1378/chest.116.5.1183 pmid:http://www.ncbi.nlm.nih.gov/pubmed/10559074
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Almatroodi SA ,
    2. McDonald CF ,
    3. Darby IA , et al
    . Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron 2016;9:1–11.doi:10.1007/s12307-015-0174-x pmid:http://www.ncbi.nlm.nih.gov/pubmed/26319408
    OpenUrlCrossRefPubMed
  31. ↵
    1. Mroz MM ,
    2. Maier LA ,
    3. Strand M , et al
    . Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. Am J Ind Med 2009;52:762–73.doi:10.1002/ajim.20736 pmid:http://www.ncbi.nlm.nih.gov/pubmed/19681064
    OpenUrlCrossRefPubMed
  32. ↵
    1. Rossi G ,
    2. Cavazza A ,
    3. Colby TV
    . Pathology of sarcoidosis. Clin Rev Allergy Immunol 2015;49:36–44.doi:10.1007/s12016-015-8479-6 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25762348
    OpenUrlPubMed
  33. ↵
    1. Ahmadzai H ,
    2. Huang S ,
    3. Steinfort C , et al
    . Sarcoidosis: a state of the art review from the thoracic Society of Australia and New Zealand. Med J Aust 2018;208:499–504.doi:10.5694/mja17.00610 pmid:http://www.ncbi.nlm.nih.gov/pubmed/29719195
    OpenUrlPubMed
  34. ↵
    1. Mitchell DN ,
    2. Scadding JG ,
    3. Heard BE , et al
    . Sarcoidosis: histopathological definition and clinical diagnosis. J Clin Pathol 1977;30:395–408.doi:10.1136/jcp.30.5.395 pmid:http://www.ncbi.nlm.nih.gov/pubmed/325017
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Soler P ,
    2. Basset F ,
    3. Bernaudin JF
    . Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann N Y Acad Sci 1976;278:147–60.doi:10.1111/j.1749-6632.1976.tb47026.x pmid:http://www.ncbi.nlm.nih.gov/pubmed/1067004
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Moller DR ,
    2. Forman JD ,
    3. Liu MC , et al
    . Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996;156:4952.pmid:http://www.ncbi.nlm.nih.gov/pubmed/8648147
    OpenUrlAbstract
  37. ↵
    1. Eubank TD ,
    2. Roberts R ,
    3. Galloway M , et al
    . GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 2004;21:831–42.doi:10.1016/j.immuni.2004.10.011 pmid:http://www.ncbi.nlm.nih.gov/pubmed/15589171
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Puren AJ ,
    2. Fantuzzi G ,
    3. Gu Y , et al
    . Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998;101:711–21.doi:10.1172/JCI1379 pmid:http://www.ncbi.nlm.nih.gov/pubmed/9449707
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Amsen D ,
    2. Spilianakis CG ,
    3. Flavell RA
    . How are T(H)1 and T(H)2 effector cells made? Curr Opin Immunol 2009;21:153–60.doi:10.1016/j.coi.2009.03.010 pmid:http://www.ncbi.nlm.nih.gov/pubmed/19375293
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Zissel G ,
    2. Müller-Quernheim J
    . Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med 2015;36:549–60.doi:10.1016/j.ccm.2015.08.016 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26593132
    OpenUrlCrossRefPubMed
  41. ↵
    1. Ramstein J ,
    2. Broos CE ,
    3. Simpson LJ , et al
    . IFN-γ-Producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med 2016;193:1281–91.doi:10.1164/rccm.201507-1499OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/26649486
    OpenUrlCrossRefPubMed
  42. ↵
    1. Urbankowski T ,
    2. Hoser G ,
    3. Domagała-Kulawik J
    . Th1/Th2/Th17‑related cytokines in the bronchoalveolar lavage fluid of patients with sarcoidosis: association with smoking. Pol Arch Med Wewn 2012;122:320–5.pmid:http://www.ncbi.nlm.nih.gov/pubmed/22814515
    OpenUrlPubMed
  43. ↵
    1. Loke WSJ ,
    2. Herbert C ,
    3. Thomas PS
    . Sarcoidosis: immunopathogenesis and immunological markers. Int J Chronic Dis 2013;2013:1–13.doi:10.1155/2013/928601 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26464848
    OpenUrlPubMed
  44. ↵
    1. Arger NK ,
    2. Machiraju S ,
    3. Allen IE , et al
    . T-Bet expression in peripheral Th17.0 cells is associated with pulmonary function changes in sarcoidosis. Front Immunol 2020;11:1129. doi:10.3389/fimmu.2020.01129 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32774332
    OpenUrlPubMed
  45. ↵
    1. Broos CE ,
    2. Hendriks RW ,
    3. Kool M
    . T-Cell immunology in sarcoidosis: disruption of a delicate balance between helper and regulatory T-cells. Curr Opin Pulm Med 2016;22:476–83.doi:10.1097/MCP.0000000000000303 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27379969
    OpenUrlCrossRefPubMed
  46. ↵
    1. Liu X ,
    2. Das AM ,
    3. Seideman J , et al
    . The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. Am J Respir Cell Mol Biol 2007;37:121–8.doi:10.1165/rcmb.2005-0253OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/17379849
    OpenUrlCrossRefPubMed
  47. ↵
    1. Xaubet A ,
    2. Marin-Arguedas A ,
    3. Lario S , et al
    . Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:431–5.doi:10.1164/rccm.200210-1165OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/12746254
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Soto-Gomez N ,
    2. Peters JI ,
    3. Nambiar AM
    . Diagnosis and management of sarcoidosis. Am Fam Physician 2016;93:840–8.pmid:http://www.ncbi.nlm.nih.gov/pubmed/27175719
    OpenUrlPubMed
  49. ↵
    1. Crouser ED ,
    2. Maier LA ,
    3. Wilson KC , et al
    . Diagnosis and detection of sarcoidosis. An official American thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020;201:e26–51.doi:10.1164/rccm.202002-0251ST
    OpenUrlCrossRef
  50. ↵
    1. Rao DA ,
    2. Dellaripa PF
    . Extrapulmonary manifestations of sarcoidosis. Rheum Dis Clin North Am 2013;39:277–97.doi:10.1016/j.rdc.2013.02.007 pmid:http://www.ncbi.nlm.nih.gov/pubmed/23597964
    OpenUrlPubMed
  51. ↵
    1. Gerke AK ,
    2. Judson MA ,
    3. Cozier YC , et al
    . Disease burden and variability in sarcoidosis. Ann Am Thorac Soc 2017;14:S421–8.doi:10.1513/AnnalsATS.201707-564OT pmid:http://www.ncbi.nlm.nih.gov/pubmed/29087725
    OpenUrlPubMed
  52. ↵
    1. Bonham CA
    . Biomarkers in sarcoidosis: can microRNAs fill the gap? Am J Respir Cell Mol Biol 2018;58:1–2.doi:10.1165/rcmb.2017-0344ED pmid:http://www.ncbi.nlm.nih.gov/pubmed/29286860
    OpenUrlPubMed
  53. ↵
    1. Belhomme N ,
    2. Jouneau S ,
    3. Bouzillé G , et al
    . Role of serum immunoglobulins for predicting sarcoidosis outcome: a cohort study. PLoS One 2018;13:e0193122. doi:10.1371/journal.pone.0193122 pmid:http://www.ncbi.nlm.nih.gov/pubmed/29641520
    OpenUrlPubMed
  54. ↵
    1. Casanova N ,
    2. Zhou T ,
    3. Knox KS , et al
    . Identifying novel biomarkers in sarcoidosis using genome-based approaches. Clin Chest Med 2015;36:621–30.doi:10.1016/j.ccm.2015.08.005 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26593137
    OpenUrlCrossRefPubMed
  55. ↵
    1. Bergantini L ,
    2. Bianchi F ,
    3. Cameli P , et al
    . Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers 2019;2019:1–7.doi:10.1155/2019/8565423 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30944672
    OpenUrlPubMed
  56. ↵
    1. Ahmadzai H ,
    2. Loke WSJ ,
    3. Huang S , et al
    . Biomarkers in sarcoidosis: a review. Curr Biomark Find 2014;4:93–106.doi:10.2147/CBF.S46196
    OpenUrl
  57. ↵
    1. Ahmadzai H ,
    2. Wakefield D ,
    3. Thomas PS
    . The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques. Inflammopharmacology 2011;19:55–68.doi:10.1007/s10787-011-0079-3 pmid:http://www.ncbi.nlm.nih.gov/pubmed/21318459
    OpenUrlPubMed
  58. ↵
    1. Sng JJ ,
    2. Prazakova S ,
    3. Thomas PS , et al
    . MMP-8, MMP-9 and neutrophil elastase in peripheral blood and exhaled breath condensate in COPD. COPD 2017;14:238–44.doi:10.1080/15412555.2016.1249790 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27880043
    OpenUrlPubMed
  59. ↵
    1. Mathew S ,
    2. Bauer KL ,
    3. Fischoeder A , et al
    . The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol 2008;181:746–55.doi:10.4049/jimmunol.181.1.746 pmid:http://www.ncbi.nlm.nih.gov/pubmed/18566441
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Chopra A ,
    2. Kalkanis A ,
    3. Judson MA
    . Biomarkers in sarcoidosis. Expert Rev Clin Immunol 2016;12:1191–208.doi:10.1080/1744666X.2016.1196135 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27253883
    OpenUrlCrossRefPubMed
  61. ↵
    1. Ascoli C ,
    2. Huang Y ,
    3. Schott C , et al
    . A circulating microRNA signature serves as a diagnostic and prognostic indicator in sarcoidosis. Am J Respir Cell Mol Biol 2018;58:40–54.doi:10.1165/rcmb.2017-0207OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/28812922
    OpenUrlPubMed
  62. ↵
    1. Bargagli E ,
    2. Bennett D ,
    3. Maggiorelli C , et al
    . Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immunol 2013;33:264–70.doi:10.1007/s10875-012-9754-4 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22878841
    OpenUrlCrossRefPubMed
  63. ↵
    1. Chen ES ,
    2. Song Z ,
    3. Willett MH , et al
    . Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010;181:360–73.doi:10.1164/rccm.200905-0696OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/19910611
    OpenUrlCrossRefPubMed
  64. ↵
    1. Eurelings LEM ,
    2. Miedema JR ,
    3. Dalm VASH , et al
    . Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One 2019;14:e0223897. doi:10.1371/journal.pone.0223897 pmid:http://www.ncbi.nlm.nih.gov/pubmed/31622413
    OpenUrlPubMed
  65. ↵
    1. Greene CM ,
    2. Meachery G ,
    3. Taggart CC , et al
    . Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 2000;165:4718–24.doi:10.4049/jimmunol.165.8.4718 pmid:http://www.ncbi.nlm.nih.gov/pubmed/11035116
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Grutters JC ,
    2. Fellrath J-M ,
    3. Mulder L , et al
    . Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003;124:186–95.doi:10.1378/chest.124.1.186 pmid:http://www.ncbi.nlm.nih.gov/pubmed/12853522
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Kahkouee S ,
    2. Samadi K ,
    3. Alai A , et al
    . Serum ACE level in sarcoidosis patients with typical and atypical HRCT manifestation. Pol J Radiol 2016;81:458–61.doi:10.12659/PJR.897708 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27733890
    OpenUrlPubMed
  68. ↵
    1. Kieszko R ,
    2. Krawczyk P ,
    3. Jankowska O , et al
    . The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respir Med 2007;101:722–8.doi:10.1016/j.rmed.2006.08.019 pmid:http://www.ncbi.nlm.nih.gov/pubmed/17015003
    OpenUrlPubMed
  69. ↵
    1. Klech H ,
    2. Kohn H ,
    3. Kummer F , et al
    . Assessment of activity in sarcoidosis. sensitivity and specificity of 67gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations. Chest 1982;82:732–8.doi:10.1378/chest.82.6.732 pmid:http://www.ncbi.nlm.nih.gov/pubmed/6291864
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. Miyoshi S ,
    2. Hamada H ,
    3. Kadowaki T , et al
    . Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010;137:1391–7.doi:10.1378/chest.09-1975 pmid:http://www.ncbi.nlm.nih.gov/pubmed/20081103
    OpenUrlCrossRefPubMedWeb of Science
  71. ↵
    1. Novick D ,
    2. Kim S ,
    3. Kaplanski G , et al
    . Interleukin-18, more than a Th1 cytokine. Semin Immunol 2013;25:439–48.doi:10.1016/j.smim.2013.10.014 pmid:http://www.ncbi.nlm.nih.gov/pubmed/24275602
    OpenUrlCrossRefPubMed
  72. ↵
    1. Ringkowski S ,
    2. Thomas PS ,
    3. Herbert C
    . Interleukin-12 family cytokines and sarcoidosis. Front Pharmacol 2014;5:233. doi:10.3389/fphar.2014.00233 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25386143
    OpenUrlPubMed
  73. ↵
    1. Su R ,
    2. Li MM ,
    3. Bhakta NR , et al
    . Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J 2014;44:985–93.doi:10.1183/09031936.00039714 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25142485
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Su R ,
    2. Nguyen M-LT ,
    3. Agarwal MR , et al
    . Interferon-Inducible chemokines reflect severity and progression in sarcoidosis. Respir Res 2013;14:121. doi:10.1186/1465-9921-14-121 pmid:http://www.ncbi.nlm.nih.gov/pubmed/24199653
    OpenUrlCrossRefPubMed
  75. ↵
    1. Thi Hong Nguyen C ,
    2. Kambe N ,
    3. Kishimoto I , et al
    . Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. J Dermatol 2017;44:789–97.doi:10.1111/1346-8138.13792 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28295528
    OpenUrlCrossRefPubMed
  76. ↵
    1. Yasar Z ,
    2. Özgül M ,
    3. Cetinkaya E
    . Angiotensin-Converting enzyme as a predictor of extrathoracic involvement of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2015;32:318–24.
    OpenUrl
  77. ↵
    1. Zhang Y ,
    2. Chen X ,
    3. Hu Y , et al
    . Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients. Respir Res 2013;14:18. doi:10.1186/1465-9921-14-18 pmid:http://www.ncbi.nlm.nih.gov/pubmed/23399022
    OpenUrlPubMed
  78. ↵
    1. Popević S ,
    2. Šumarac Z ,
    3. Jovanović D , et al
    . Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis - a Case-control Study. J Med Biochem 2016;35:390–400.doi:10.1515/jomb-2016-0017 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28670191
    OpenUrlPubMed
  79. ↵
    1. Ungprasert P ,
    2. Carmona EM ,
    3. Crowson CS , et al
    . Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung 2016;194:91–5.doi:10.1007/s00408-015-9826-3 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26563332
    OpenUrlPubMed
  80. ↵
    1. Du S-S ,
    2. Zhao M-M ,
    3. Zhang Y , et al
    . Screening for differentially expressed proteins relevant to the differential diagnosis of sarcoidosis and tuberculosis. PLoS One 2015;10:e0132466. doi:10.1371/journal.pone.0132466 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26368286
    OpenUrlPubMed
  81. ↵
    1. Kobak S ,
    2. Semiz H ,
    3. Akyildiz M , et al
    . Serum adipokine levels in patients with sarcoidosis. Clin Rheumatol 2020;39:2121–5.doi:10.1007/s10067-020-04980-1 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32060810
    OpenUrlPubMed
  82. ↵
    1. Tanimura H ,
    2. Mizuno K ,
    3. Okamoto H
    . Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2015;32:99–105.pmid:http://www.ncbi.nlm.nih.gov/pubmed/26278688
    OpenUrlPubMed
  83. ↵
    1. Kiko T ,
    2. Yoshihisa A ,
    3. Kanno Y , et al
    . A multiple biomarker approach in patients with cardiac sarcoidosis. Int Heart J 2018;59:996–1001.doi:10.1536/ihj.17-695 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30101857
    OpenUrlPubMed
  84. ↵
    1. Perez IE ,
    2. Garcia MJ ,
    3. Taub CC
    . Multimodality imaging in cardiac sarcoidosis: is there a winner? Curr Cardiol Rev 2016;12:3–11.doi:10.2174/1573403X11666150318110406 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25784137
    OpenUrlPubMed
  85. ↵
    1. Moss BP ,
    2. Patel DC ,
    3. Tavee JO , et al
    . Evaluating S100B as a serum biomarker for central neurosarcoidosis. Respir Med 2020;162:105855. doi:10.1016/j.rmed.2019.105855 pmid:http://www.ncbi.nlm.nih.gov/pubmed/31916532
    OpenUrlPubMed
  86. ↵
    1. Danila E ,
    2. Jurgauskiene L ,
    3. Norkuniene J , et al
    . BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity. Ups J Med Sci 2009;114:26–31.doi:10.1080/03009730802579729 pmid:http://www.ncbi.nlm.nih.gov/pubmed/19242869
    OpenUrlPubMed
  87. ↵
    1. Shen Y ,
    2. Pang C ,
    3. Wu Y , et al
    . Diagnostic performance of bronchoalveolar lavage fluid CD4/CD8 ratio for sarcoidosis: a meta-analysis. EBioMedicine 2016;8:302–8.doi:10.1016/j.ebiom.2016.04.024 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27428439
    OpenUrlPubMed
  88. ↵
    1. Crouser ED ,
    2. Culver DA ,
    3. Knox KS , et al
    . Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009;179:929–38.doi:10.1164/rccm.200803-490OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/19218196
    OpenUrlCrossRefPubMedWeb of Science
  89. ↵
    1. Mohan A ,
    2. Neequaye N ,
    3. Malur A , et al
    . Matrix metalloproteinase-12 is required for granuloma progression. Front Immunol 2020;11:553949. doi:10.3389/fimmu.2020.553949 pmid:http://www.ncbi.nlm.nih.gov/pubmed/33072094
    OpenUrlPubMed
  90. ↵
    1. Darlington P ,
    2. Kullberg S ,
    3. Eklund A , et al
    . Subpopulations of cells from bronchoalveolar lavage can predict prognosis in sarcoidosis. Eur Respir J 2020;55. doi:doi:10.1183/13993003.01450-2019. [Epub ahead of print: 30 01 2020].pmid:http://www.ncbi.nlm.nih.gov/pubmed/31439687
  91. ↵
    1. Idali F ,
    2. Wikén M ,
    3. Wahlström J , et al
    . Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J 2006;27:451–9.doi:10.1183/09031936.06.00067105 pmid:http://www.ncbi.nlm.nih.gov/pubmed/16507843
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Lim MY ,
    2. Thomas PS
    . Biomarkers in exhaled breath condensate and serum of chronic obstructive pulmonary disease and non-small-cell lung cancer. Int J Chronic Dis 2013;2013:1–15.doi:10.1155/2013/578613 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26464846
    OpenUrlPubMed
  93. ↵
    1. Leiten EO ,
    2. Martinsen EMH ,
    3. Bakke PS , et al
    . Complications and discomfort of bronchoscopy: a systematic review. Eur Clin Respir J 2016;3:33324.doi:10.3402/ecrj.v3.33324 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27839531
    OpenUrlPubMed
  94. ↵
    1. Montuschi P
    . Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Ther Adv Respir Dis 2007;1:5–23.doi:10.1177/1753465807082373 pmid:http://www.ncbi.nlm.nih.gov/pubmed/19124344
    OpenUrlCrossRefPubMed
  95. ↵
    1. Jackson AS ,
    2. Sandrini A ,
    3. Campbell C , et al
    . Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am J Respir Crit Care Med 2007;175:222–7.doi:10.1164/rccm.200601-107OC pmid:http://www.ncbi.nlm.nih.gov/pubmed/17110649
    OpenUrlCrossRefPubMedWeb of Science
  96. ↵
    1. Gessner C ,
    2. Scheibe R ,
    3. Wötzel M , et al
    . Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005;99:1229–40.doi:10.1016/j.rmed.2005.02.041 pmid:http://www.ncbi.nlm.nih.gov/pubmed/16140223
    OpenUrlCrossRefPubMedWeb of Science
  97. ↵
    1. Montuschi P ,
    2. Kharitonov SA ,
    3. Ciabattoni G , et al
    . Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585–8.doi:10.1136/thorax.58.7.585 pmid:http://www.ncbi.nlm.nih.gov/pubmed/12832671
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Klaassen EMM ,
    2. Kant KDGvande ,
    3. Jöbsis Q , et al
    . Symptoms, but not a biomarker response to inhaled corticosteroids, predict asthma in preschool children with recurrent wheeze. Mediators Inflamm 2012;2012:1–7.doi:10.1155/2012/162571 pmid:http://www.ncbi.nlm.nih.gov/pubmed/23304059
    OpenUrlCrossRefPubMed
  99. ↵
    1. Zietkowski Z ,
    2. Tomasiak MM ,
    3. Skiepko R , et al
    . Rantes in exhaled breath condensate of stable and unstable asthma patients. Respir Med 2008;102:1198–202.doi:10.1016/j.rmed.2008.03.010 pmid:http://www.ncbi.nlm.nih.gov/pubmed/18603420
    OpenUrlCrossRefPubMed
  100. ↵
    1. Mohan N ,
    2. Akter R ,
    3. Bryant K , et al
    . Exhaled breath markers of alveolar macrophage activity in sarcoidosis. Inflamm Res 2016;65:471–8.doi:10.1007/s00011-016-0929-y pmid:http://www.ncbi.nlm.nih.gov/pubmed/27007332
    OpenUrlPubMed
  101. ↵
    1. Hamsten C ,
    2. Wiklundh E ,
    3. Grönlund H , et al
    . Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients. Respir Res 2016;17:69. doi:10.1186/s12931-016-0381-0 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27259755
    OpenUrlPubMed
  102. ↵
    1. Ahmadzai H ,
    2. Cameron B ,
    3. Chui J , et al
    . Measurement of neopterin, TGF-β1 and ACE in the exhaled breath condensate of patients with sarcoidosis. J Breath Res 2013;7:046003. doi:10.1088/1752-7155/7/4/046003 pmid:http://www.ncbi.nlm.nih.gov/pubmed/24091835
    OpenUrlPubMed
  103. ↵
    1. Loke WSJ ,
    2. Freeman A ,
    3. Garthwaite L , et al
    . T-Bet and interleukin-27: possible TH1 immunomodulators of sarcoidosis. Inflammopharmacology 2015;23:283–90.doi:10.1007/s10787-015-0247-y pmid:http://www.ncbi.nlm.nih.gov/pubmed/26254778
    OpenUrlPubMed
  104. ↵
    1. Alipoor SD ,
    2. Mortaz E ,
    3. Garssen J , et al
    . Exosomes and exosomal miRNA in respiratory diseases. Mediators Inflamm 2016;2016:1–11.doi:10.1155/2016/5628404 pmid:http://www.ncbi.nlm.nih.gov/pubmed/27738390
    OpenUrlCrossRefPubMed
  105. ↵
    1. Kishore A ,
    2. Navratilova Z ,
    3. Kolek V , et al
    . Expression analysis of extracellular microRNA in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respirology 2018;23:1166–72.doi:10.1111/resp.13364 pmid:http://www.ncbi.nlm.nih.gov/pubmed/29956871
    OpenUrlPubMed
  106. ↵
    1. Scheideler L ,
    2. Manke HG ,
    3. Schwulera U , et al
    . Detection of nonvolatile macromolecules in breath. A possible diagnostic tool? Am Rev Respir Dis 1993;148:778–84.doi:10.1164/ajrccm/148.3.778 pmid:http://www.ncbi.nlm.nih.gov/pubmed/8368649
    OpenUrlCrossRefPubMedWeb of Science
  107. ↵
    1. Qazi KR ,
    2. Torregrosa Paredes P ,
    3. Dahlberg B , et al
    . Proinflammatory exosomes in bronchoalveolar lavage fluid of patients with sarcoidosis. Thorax 2010;65:1016–24.doi:10.1136/thx.2009.132027 pmid:http://www.ncbi.nlm.nih.gov/pubmed/20880880
    OpenUrlAbstract/FREE Full Text
  108. ↵
    1. Costabel U ,
    2. Hunninghake GW
    . ATS/ERS/WASOG statement on sarcoidosis. sarcoidosis statement Committee. American thoracic Society. European respiratory Society. world association for sarcoidosis and other granulomatous disorders. Eur Respir J 1999;14:735. doi:10.1034/j.1399-3003.1999.14d02.x pmid:http://www.ncbi.nlm.nih.gov/pubmed/10573213
    OpenUrlFREE Full Text
  109. ↵
    1. Baughman RP ,
    2. Nagai S ,
    3. Balter M , et al
    . Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task force. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:56–64.pmid:http://www.ncbi.nlm.nih.gov/pubmed/21796892
    OpenUrlPubMedWeb of Science
  110. ↵
    1. Salamo O ,
    2. Mortaz E ,
    3. Mirsaeidi M
    . Noncoding RNAs: new players in pulmonary medicine and sarcoidosis. Am J Respir Cell Mol Biol 2018;58:147–56.doi:10.1165/rcmb.2017-0196TR pmid:http://www.ncbi.nlm.nih.gov/pubmed/28850258
    OpenUrlPubMed
  111. ↵
    1. Brown D ,
    2. Rahman M ,
    3. Nana-Sinkam SP
    . Micrornas in respiratory disease. A clinician's overview. Ann Am Thorac Soc 2014;11:1277–85.doi:10.1513/AnnalsATS.201404-179FR pmid:http://www.ncbi.nlm.nih.gov/pubmed/25172373
    OpenUrlPubMed
  112. ↵
    1. Bak M ,
    2. Jazwa A ,
    3. Kasper L , et al
    . Involvement of microRNAs in the inflammatory pathways of pulmonary sarcoidosis. J Physiol Pharmacol 2015;66:635–42.pmid:http://www.ncbi.nlm.nih.gov/pubmed/26579569
    OpenUrlPubMed
  113. ↵
    1. Bartel DP
    . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.doi:10.1016/s0092-8674(04)00045-5 pmid:http://www.ncbi.nlm.nih.gov/pubmed/14744438
    OpenUrlCrossRefPubMedWeb of Science
  114. ↵
    1. Pattnaik B ,
    2. Sryma PB ,
    3. Mittal S , et al
    . MicroRNAs in pulmonary sarcoidosis: a systematic review. Respir Investig 2020;58:232–8.doi:10.1016/j.resinv.2020.02.008 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32305227
    OpenUrlPubMed
  115. ↵
    1. Jazwa A ,
    2. Kasper L ,
    3. Bak M , et al
    . Differential inflammatory microRNA and cytokine expression in pulmonary sarcoidosis. Arch Immunol Ther Exp 2015;63:139–46.doi:10.1007/s00005-014-0315-9 pmid:http://www.ncbi.nlm.nih.gov/pubmed/25366387
    OpenUrlPubMed
  116. ↵
    1. Novosadová E ,
    2. Chabronova A ,
    3. Kolek V , et al
    . The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome. Mediators Inflamm 2016;2016:1–12.doi:10.1155/2016/1246129
    OpenUrlCrossRefPubMed
  117. ↵
    1. Nana-Sinkam SP ,
    2. Acunzo M ,
    3. Croce CM , et al
    . Extracellular vesicle biology in the pathogenesis of lung disease. Am J Respir Crit Care Med 2017;196:1510–8.doi:10.1164/rccm.201612-2457PP pmid:http://www.ncbi.nlm.nih.gov/pubmed/28678586
    OpenUrlPubMed
  118. ↵
    1. Kalluri R ,
    2. LeBleu VS
    . Discovery of double-stranded genomic DNA in circulating exosomes. Cold Spring Harb Symp Quant Biol 2016;81:275–80.doi:10.1101/sqb.2016.81.030932 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28424339
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Gallo A ,
    2. Tandon M ,
    3. Alevizos I , et al
    . The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679. doi:10.1371/journal.pone.0030679 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22427800
    OpenUrlCrossRefPubMed
  120. ↵
    1. Arroyo JD ,
    2. Chevillet JR ,
    3. Kroh EM , et al
    . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011;108:5003–8.doi:10.1073/pnas.1019055108 pmid:http://www.ncbi.nlm.nih.gov/pubmed/21383194
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Turchinovich A ,
    2. Weiz L ,
    3. Langheinz A , et al
    . Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223–33.doi:10.1093/nar/gkr254 pmid:http://www.ncbi.nlm.nih.gov/pubmed/21609964
    OpenUrlCrossRefPubMedWeb of Science
  122. ↵
    1. Momen-Heravi F ,
    2. Saha B ,
    3. Kodys K , et al
    . Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med 2015;13:261. doi:10.1186/s12967-015-0623-9 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26264599
    OpenUrlCrossRefPubMed
  123. ↵
    1. Kishore A ,
    2. Navratilova Z ,
    3. Kolek V
    . Detection of exosomal miRNA in pulmonary sarcoidosis. Eur Res J 2014.
  124. ↵
    1. Hng Y ,
    2. Waters S ,
    3. Chen Y
    . Exosome-related mediators in serum and exhaled breath condensate in sarcoidosis. Respirology 2019;24:116.
    OpenUrl
  125. ↵
    1. Crouser ED ,
    2. Julian MW ,
    3. Crawford M , et al
    . Differential expression of microRNA and predicted targets in pulmonary sarcoidosis. Biochem Biophys Res Commun 2012;417:886–91.doi:10.1016/j.bbrc.2011.12.068 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22209793
    OpenUrlCrossRefPubMed
  126. ↵
    1. Dyskova T ,
    2. Fillerova R ,
    3. Novosad T , et al
    . Correlation network analysis reveals relationships between microRNAs, transcription factor T-bet, and deregulated Cytokine/Chemokine-Receptor network in pulmonary sarcoidosis. Mediators Inflamm 2015;2015:1–16.doi:10.1155/2015/121378 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26696750
    OpenUrlCrossRefPubMed
  127. ↵
    1. Kiszałkiewicz J ,
    2. Piotrowski WJ ,
    3. Pastuszak-Lewandoska D , et al
    . Altered miRNA expression in pulmonary sarcoidosis. BMC Med Genet 2016;17:2. doi:10.1186/s12881-016-0266-6 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26768132
    OpenUrlPubMed
  128. ↵
    1. Lee H ,
    2. Groot M ,
    3. Pinilla-Vera M , et al
    . Identification of miRNA-rich vesicles in bronchoalveolar lavage fluid: insights into the function and heterogeneity of extracellular vesicles. J Control Release 2019;294:43–52.doi:10.1016/j.jconrel.2018.12.008 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30529727
    OpenUrlPubMed
  129. ↵
    1. Maertzdorf J ,
    2. Weiner J ,
    3. Mollenkopf H-J , et al
    . Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 2012;109:7853–8.doi:10.1073/pnas.1121072109 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22547807
    OpenUrlAbstract/FREE Full Text
  130. ↵
    1. Novosadova E ,
    2. Chabronova A ,
    3. Kolek V , et al
    . The serum expression of selected miRNAs in pulmonary sarcoidosis with/without Löfgren's syndrome. Mediators Inflamm 2016;2016:1–12.doi:10.1155/2016/1246129 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28050119
    OpenUrlCrossRefPubMed
  131. ↵
    1. Tomankova T ,
    2. Zurkova M ,
    3. Kolek V
    . Microrna profiling revealed downregulated miR-204 expression in bronchoalveolar cells from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2020;201:A1207.
  132. ↵
    1. Crouser ED ,
    2. Hamzeh NY ,
    3. Maier LA , et al
    . Exosomal microRNA for detection of cardiac sarcoidosis. Am J Respir Crit Care Med 2017;196:931–4.doi:10.1164/rccm.201611-2183LE pmid:http://www.ncbi.nlm.nih.gov/pubmed/28245138
    OpenUrlPubMed
    1. Landi C ,
    2. Carleo A ,
    3. Cillis G , et al
    . Sarcoidosis: proteomics and new perspectives for improving personalized medicine. Expert Rev Proteomics 2018;15:829–35.doi:10.1080/14789450.2018.1528148 pmid:http://www.ncbi.nlm.nih.gov/pubmed/30251559
    OpenUrlPubMed
    1. Zhou T ,
    2. Casanova N ,
    3. Pouladi N , et al
    . Identification of JAK-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep 2017;7:4237. doi:10.1038/s41598-017-04109-6 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28652588
    OpenUrlPubMed
    1. Mroz RM ,
    2. Korniluk M ,
    3. Stasiak-Barmuta A , et al
    . Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol 2008;59 Suppl 6:507–13.pmid:http://www.ncbi.nlm.nih.gov/pubmed/19218675
    OpenUrlPubMed
    1. Pokorski M
    1. Naumnik W ,
    2. Naumnik B ,
    3. Niklińska W
    . Interleukin-33 as a New Marker of Pulmonary Sarcoidosis. In: Pokorski M , ed. Noncommunicable diseases. Cham: Springer international publishing, 2015: 1–6.
    1. Thillai M ,
    2. Eberhardt C ,
    3. Lewin AM , et al
    . Sarcoidosis and tuberculosis cytokine profiles: indistinguishable in bronchoalveolar lavage but different in blood. PLoS One 2012;7:e38083. doi:10.1371/journal.pone.0038083 pmid:http://www.ncbi.nlm.nih.gov/pubmed/22815689
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 69 Issue 4 Table of Contents
Journal of Investigative Medicine: 69 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potential use of biomarkers for the clinical evaluation of sarcoidosis
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Potential use of biomarkers for the clinical evaluation of sarcoidosis
Amir Mousapasandi, Cristan Herbert, Paul Thomas
Journal of Investigative Medicine Apr 2021, 69 (4) 804-813; DOI: 10.1136/jim-2020-001659

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Potential use of biomarkers for the clinical evaluation of sarcoidosis
Amir Mousapasandi, Cristan Herbert, Paul Thomas
Journal of Investigative Medicine Apr 2021, 69 (4) 804-813; DOI: 10.1136/jim-2020-001659
Download PDF

Share
Potential use of biomarkers for the clinical evaluation of sarcoidosis
Amir Mousapasandi, Cristan Herbert, Paul Thomas
Journal of Investigative Medicine Apr 2021, 69 (4) 804-813; DOI: 10.1136/jim-2020-001659
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Abstract
    • Background
    • Biomarkers for clinical evaluation
    • Discovery and validation of novel biomarkers
    • Conclusion and future research
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucocorticoid therapy in respiratory illness: bench to bedside
  • Remote patient monitoring in the management of chronic obstructive pulmonary disease
  • Expanded hemodialysis: a new concept of renal replacement therapy
Show more Review

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2023 American Federation for Medical Research